ATF3 and neoplasm: Current evidence points towards the importance of tumor-initiating receptor-ligand interactions, e.g., FcγR-antibody complexes, TCR-MHC engagement (Miyake and Karasuyama, 2021), CD47-SIRPα signalling (Park et al., 2022), cell intrinsic regulators such as CH25H mediated cholesterol metabolism and ATF3 transcriptional control within the TME (Lu et al., 2022).